Mavacamten use has been associated with reducing systolic function, manifesting as worsening functional capacity and heart failure exacerbation. However, no carcinogenic or mutagenic effects have been linked to Mavacamten. In animal studies, QT prolongation and cardiac osseous metaplasia were reported when exposed to doses up to 10 mg/kg/day.